Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Janssen Sciences Ireland UC
Sponsor:
Information provided by (Responsible Party):
Janssen Sciences Ireland UC
ClinicalTrials.gov Identifier:
NCT00799864
First received: November 26, 2008
Last updated: November 12, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2024
  Estimated Primary Completion Date: January 2020 (Final data collection date for primary outcome measure)